- Home
- NLY vs ROIV Comparison
NLY vs ROIV Comparison
Compare NLY & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NLY | ROIV |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 14.1B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | NLY | ROIV |
|---|---|---|
| Price | $22.75 | $22.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $21.63 | ★ $24.31 |
| AVG Volume (30 Days) | 7.0M | ★ 7.9M |
| Earning Date | 01-28-2026 | 11-10-2025 |
| Dividend Yield | ★ 12.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $1,748,174,000.00 | $20,329,000.00 |
| Revenue This Year | $358.71 | N/A |
| Revenue Next Year | $8.02 | $376.94 |
| P/E Ratio | $10.30 | ★ N/A |
| Revenue Growth | ★ 275.23 | N/A |
| 52 Week Low | $16.60 | $8.73 |
| 52 Week High | $22.98 | $23.47 |
Technical Indicators
Market Signals| Indicator | NLY | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 60.82 |
| Support Level | $22.10 | $21.60 |
| Resistance Level | $22.52 | $23.47 |
| Average True Range (ATR) | 0.29 | 0.86 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 78.29 | 65.24 |
Price Performance
Historical ComparisonAbout NLY Annaly Capital Management Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are; the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.